🔗 Share this article

The first new treatments for gonorrhoea in many years are being described as a "major milestone" in the fight against drug-resistant strains of the infection, according to researchers.

An International Health Concern

Cases of gonorrhoea are on the rise around the world, with data suggesting more than 82 million infections annually. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an critical and opportune advancement in the reality of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Public health authorities are increasingly worried about the rise in treatment-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Recent Therapies Gain Approval

One new antibiotic, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers anticipate that targeted use of this new drug will help slow the emergence of superbugs.

Gepotidacin, originating from the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This treatment, which is employed against UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP partnered with the drug firm Innoviva to develop it.

“This milestone signifies a huge turning point in the therapy of superbug gonorrhoea, which previously has been outpacing our drug pipeline.”

Research Study Data and Global Access

As per results released by a prominent scientific publication, the new drug successfully treated the vast majority of cases of the STI. This puts it on an comparable level with the current standard treatment, which uses two antibiotics. The research involved nearly 1,000 volunteers from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in many low-income and middle-income countries.

Doctors directly involved have shared hope. Access to a easy-to-administer therapy of this kind is hailed as a "critical tool" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.